How to Get Fosamax (Alendronate) in Colorado

What Is Alendronate and Why Is It Prescribed?

Alendronate is a first-line oral bisphosphonate approved by the FDA for osteoporosis prevention and treatment in postmenopausal women, men with osteoporosis, and patients on long-term glucocorticoid therapy. The drug works by inhibiting osteoclast-mediated bone resorption, slowing bone loss and reducing fracture risk. The 70 mg once-weekly tablet is the most prescribed formulation in the United States because once-weekly dosing produces equivalent efficacy to daily 10 mg dosing with a simpler schedule that most patients can maintain.

The FDA first approved alendronate sodium under the brand name Fosamax in 1995, and generic versions have been available since 2008, making it one of the most cost-accessible prescription bone therapies on the market [1]. The American Association of Clinical Endocrinologists (AACE) and the Endocrine Society both list alendronate as a first-line agent for postmenopausal osteoporosis when fracture risk is moderate to high [2].

Roughly 10.2 million Americans have osteoporosis, and an additional 43.4 million have low bone mass, according to the Bone Health and Osteoporosis Foundation [3]. Colorado's aging population follows national trends, making access to alendronate a frequent and practical clinical question across the state.

How to Get a Fosamax Prescription in Colorado

Colorado residents have two main pathways to obtain a Fosamax prescription: an in-person visit with a licensed Colorado prescriber, or a telehealth consultation with a provider licensed in Colorado. Both pathways require a documented medical evaluation including a review of your fracture history, fall risk, and bone density results before a prescription can be written.

Colorado enacted comprehensive telehealth parity legislation that requires insurers to reimburse telehealth visits at the same rate as in-person visits for covered services [4]. That law, combined with Colorado's adoption of the Interstate Medical Licensure Compact, means many national telehealth platforms operate legally in Colorado and can prescribe alendronate without requiring you to travel to a physical clinic.

The minimum clinical steps before a prescription is issued typically look like this: (1) a medical history intake, (2) a DXA scan result showing a T-score of -2.5 or below (or -1.0 to -2.5 with additional risk factors), (3) lab work reviewed by the provider, and (4) a documented shared decision-making discussion about treatment alternatives. Providers who skip these steps are practicing outside standard of care guidelines set by the National Osteoporosis Foundation [5].

Labs and Imaging Required Before Starting Alendronate

Four baseline assessments are standard before any Colorado prescriber writes the first alendronate prescription. Missing any one of them puts both patient safety and prescriber liability at risk.

DXA (dual-energy X-ray absorptiometry) bone density scan. The USPSTF recommends DXA screening for all women aged 65 and older, and for younger postmenopausal women whose 10-year fracture risk (calculated by FRAX) equals or exceeds that of a 65-year-old white woman with no additional risk factors [6]. Most Colorado imaging centers, including those within UCHealth, SCL Health, and Centura Health networks, offer DXA scanning. Self-pay cost runs $100, $250 at most facilities.

Serum calcium. Hypercalcemia is a contraindication to alendronate. A serum calcium above 10.5 mg/dL must be evaluated and corrected before treatment begins [7]. The FDA prescribing label explicitly lists hypercalcemia of any cause as a contraindication [1].

Serum 25-OH vitamin D. Hypocalcemia is a known risk with bisphosphonate therapy when baseline vitamin D is deficient. The Endocrine Society recommends maintaining serum 25-OH vitamin D at or above 30 ng/mL before starting any bisphosphonate [8]. In Colorado, at elevations above 5,000 feet, sun exposure is less reliable year-round, and testing often reveals subclinical deficiency even in active outdoor patients.

Basic metabolic panel (BMP) with creatinine and eGFR. Alendronate is contraindicated when eGFR falls below 35 mL/min/1.73 m² because the drug accumulates in bone at levels that have not been studied in severe renal impairment [1]. A BMP catches this before harm can occur.

Some providers also order a serum PTH level to rule out secondary hyperparathyroidism as a driver of bone loss. That test is not universally required by guidelines but is considered good clinical practice when the cause of low bone density is unclear [9].

Telehealth Providers Prescribing Fosamax in Colorado

Several telehealth platforms now serve Colorado patients seeking osteoporosis management. Colorado's telehealth prescribing rules allow any provider holding an active Colorado medical license to prescribe Schedule-exempt medications, including alendronate, via synchronous audio-video visits without a prior in-person relationship [4].

Platforms that connect patients with Colorado-licensed physicians, nurse practitioners, or physician assistants can legally write alendronate prescriptions after a qualifying telehealth encounter. HealthRX operates under these same rules, meaning a Colorado patient can complete an intake, submit their DXA scan and lab results digitally, conduct a live video visit, and receive a prescription sent to their preferred Colorado pharmacy, typically within 24 to 48 hours of visit completion.

The HealthRX Colorado Alendronate Access Framework guides patients through a five-step digital pathway: (1) online symptom and fracture-risk intake using the validated FRAX calculator, (2) electronic upload of existing DXA and lab results or a referral order for local imaging, (3) synchronous video visit with a Colorado-licensed prescriber averaging 18 minutes in duration, (4) electronic prescription transmission to the patient's chosen pharmacy, and (5) a 90-day follow-up message to assess tolerability and GI side effects. This structured approach aligns with the AACE 2020 postmenopausal osteoporosis clinical practice guidelines, which call for individualized treatment planning and monitoring [2].

A 2023 systematic review published in the Journal of Medical Internet Research found that telehealth-delivered osteoporosis care produced adherence rates comparable to in-person care when the platform included structured follow-up [10]. Colorado's telehealth infrastructure, supported by the Colorado Telehealth Network, makes this model particularly accessible in rural counties such as Moffat, Costilla, and Mineral, where in-person endocrinology or rheumatology access may be limited.

Who Can Prescribe Fosamax in Colorado?

Colorado authorizes a broader scope of practice for advanced practice providers than many other states. Under Colorado Revised Statutes Title 12, the following licensed providers may independently prescribe alendronate without requiring physician supervision or a collaborative practice agreement:

Medical doctors (MD) and doctors of osteopathic medicine (DO) practicing under a full Colorado license may prescribe alendronate without restriction. Nurse practitioners (NP) with a full practice authority designation in Colorado may independently prescribe alendronate; Colorado granted full NP practice authority in 2020, removing the prior requirement for a physician collaboration agreement [11]. Physician assistants (PA) in Colorado currently prescribe under a delegation agreement with a supervising physician, meaning a PA may write your alendronate prescription as long as their supervising physician has authorized osteoporosis management within the practice's delegation protocols [11].

Certified Nurse Midwives (CNMs) may also prescribe alendronate within their scope when treating postmenopausal bone loss in patients they manage.

The practical takeaway: you do not need to see an MD or a bone specialist. A Colorado-licensed NP through a telehealth platform carries the same legal prescribing authority for this medication as a hospital-based endocrinologist.

Colorado Pharmacy Access and Dispensing Options

Once a prescription is written, Colorado patients have several dispensing routes.

Retail pharmacies. Every major chain, including Walgreens, CVS, King Soopers Pharmacy, Safeway Pharmacy, and Walmart Pharmacy, stocks generic alendronate 70 mg tablets. GoodRx coupons typically bring the 30-tablet (30-week supply) cost to $12, $22 at most Denver metro locations. Rural Colorado pharmacy access is more variable, but mail-order fulfillment through the same chains resolves most availability gaps.

Mail-order pharmacies. Most commercial insurance plans cover 90-day mail-order supplies of generic alendronate at the Tier 1 generic copay, which commonly runs $0, $10 per quarter for members. Express Scripts, OptumRx, and Caremark all contract with Colorado-based health plans.

503A compounding pharmacies. Colorado-licensed 503A compounding pharmacies are authorized to prepare and dispense patient-specific compounded formulations of alendronate under a valid prescription. Compounding is rarely necessary for this drug because the commercial generic is inexpensive and widely available, but patients with documented intolerances to specific tablet excipients may benefit from a compounded alternative. The Colorado State Board of Pharmacy maintains licensing and inspection authority over all in-state 503A compounders [12].

Specialty pharmacy considerations. Standard alendronate does not require specialty pharmacy dispensing. It is not a REMS-restricted medication. Any licensed Colorado pharmacy can fill it.

Insurance Coverage and Prior Authorization in Colorado

Generic alendronate sits on Tier 1 of most Colorado commercial formularies, meaning prior authorization is not typically required. Most Blue Cross Blue Shield of Colorado, Cigna, Aetna, and United Healthcare plans cover generic alendronate at $0, $10 per fill with no prior authorization when the prescribing diagnosis code is osteoporosis (M81.0, M81.6, or M80 series).

Colorado Medicaid (Health First Colorado) does not cover alendronate for osteoporosis indications. The state Medicaid formulary restricts bisphosphonate coverage to specific diabetes-adjacent metabolic conditions; osteoporosis treatment coverage under Colorado Medicaid is limited. Patients relying on Medicaid should plan to use a GoodRx or similar discount card at a retail pharmacy, where generic alendronate's out-of-pocket cost is low enough to make this a manageable expense for most patients.

When prior authorization is required. Some Medicare Part D plans and a minority of commercial plans do require prior authorization for alendronate if the prescriber orders brand-name Fosamax rather than the generic. In those cases, the prescriber must document that the brand-name product is medically necessary, which is a difficult clinical argument given the identical active ingredient. Switching to generic eliminates the prior authorization requirement in almost every case.

If a PA is required for a specific plan, the documentation typically needed includes: DXA scan report showing T-score at or below -2.5, prescribing diagnosis code, clinical notes documenting fracture risk assessment, and confirmation that calcium and vitamin D supplementation have been initiated or are planned. Most plans process PA requests within 1, 3 business days when complete documentation is submitted electronically [13].

Clinical Evidence Supporting Alendronate

Alendronate's fracture-risk reduction data are among the strongest of any oral osteoporosis medication. The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027 women with low femoral neck bone density), found that alendronate reduced the risk of hip fracture by 47% compared to placebo (relative risk 0.53 to 95% CI 0.31, 0.90, P<0.05) and reduced vertebral fracture risk by 44% over 36 months [14]. This remains one of the landmark bisphosphonate trials and is directly cited in every major osteoporosis treatment guideline.

The AACE 2020 clinical practice guidelines state: "Alendronate, risedronate, zoledronic acid, and denosumab are recommended as initial pharmacologic therapy for postmenopausal women at high risk of fracture" [2]. The Endocrine Society's 2019 guideline on pharmacological management of osteoporosis in postmenopausal women similarly positions alendronate as a first-line option, emphasizing that "bisphosphonates reduce the risk of vertebral, nonvertebral, and hip fractures" [8].

A Cochrane systematic review of alendronate for primary and secondary prevention of osteoporotic fractures (2008, updated with subsequent trials) covering more than 11,000 participants found that alendronate reduced new vertebral fractures by 45% (relative risk 0.55 to 95% CI 0.43, 0.69) and hip fractures by 40% (relative risk 0.61 to 95% CI 0.40, 0.92) compared with placebo or calcium/vitamin D alone [15].

Bone mineral density gains are also measurable and clinically meaningful. A 3-year treatment course typically produces a 5 to 8% increase in lumbar spine BMD and a 2 to 3% increase at the femoral neck, as documented in the original key trials submitted for FDA approval [1].

Administration Instructions That Affect Efficacy

How a patient takes alendronate matters as much as whether they take it. Esophageal irritation and poor absorption are the two most common problems with bisphosphonate therapy, and both are directly tied to administration technique.

Take the 70 mg weekly tablet first thing in the morning, at least 30 minutes before any food, drink (other than plain water), or other medication. The patient must swallow the tablet with 6, 8 ounces of plain water while remaining upright (sitting or standing). Lying down within 30 minutes of the dose is contraindicated because of the risk of esophageal ulceration [1].

Calcium supplements, antacids, and iron products all substantially reduce alendronate absorption. Patients who take these medications should schedule them at a different time of day, ideally midday or evening [7]. Coffee, orange juice, and even mineral water interfere with absorption when consumed within 30 minutes of the dose.

Active esophageal disease, including Barrett's esophagus, esophageal stricture, and achalasia, is a contraindication. Patients with active upper GI problems who need osteoporosis treatment can discuss alternative agents with their provider, including intravenous zoledronic acid (Reclast), which avoids the GI tract entirely [8].

Transferring an Existing Fosamax Prescription to Colorado

Patients who move to Colorado from another state, or who already have an alendronate prescription from an out-of-state provider, can transfer that prescription to any licensed Colorado pharmacy. Federal law and Colorado pharmacy regulations permit the transfer of a non-controlled substance prescription from any licensed pharmacy in another state to a licensed Colorado pharmacy, including mail-order pharmacies registered to operate in Colorado [12].

The receiving Colorado pharmacy will contact the originating pharmacy directly. You will need the prescribing provider's name, the pharmacy name and phone number, and your prescription number. Most transfers complete within one business day.

One important caveat: if your out-of-state prescribing provider does not hold a Colorado medical license, they cannot continue to send new prescriptions to a Colorado pharmacy once you establish residency. Colorado requires that prescribers be licensed in the state where the patient is located at the time of the telehealth visit. You would need a new prescription from a Colorado-licensed provider after your initial supply runs out. A telehealth visit through HealthRX or a comparable Colorado-licensed platform is the fastest route to continuity of care in that situation.

Monitoring After Starting Alendronate

Starting alendronate is not a set-and-forget decision. Repeat DXA scanning is standard at 1 to 2 years after initiation to confirm treatment response, then every 2 years thereafter for patients who are stable [5]. Providers look for either a gain in BMD or stability (defined as no statistically significant loss) as evidence of adequate response.

A 2019 analysis in the Journal of Bone and Mineral Research (N=6,459) found that women who had no DXA follow-up were significantly more likely to discontinue therapy within 2 years compared with those who received structured monitoring [16]. Adherence to alendronate is a known clinical problem. At 1 year, roughly 50% of patients have discontinued therapy, and at 5 years that figure rises above 70%, according to data from large pharmacy claims databases [17].

The standard monitoring panel after initiation includes: repeat DXA at 1 to 2 years, serum calcium and 25-OH vitamin D annually, and a clinical assessment for jaw pain or new thigh/groin pain at every visit (to screen for the rare but serious adverse effects of osteonecrosis of the jaw and atypical femur fracture) [2].

After 5 years of continuous alendronate therapy in patients at moderate fracture risk, a drug holiday of 2 to 3 years is commonly discussed. The FLEX trial (N=1,099) showed that patients at lower baseline fracture risk who paused alendronate after 5 years did not experience significantly higher rates of nonvertebral fractures compared to those who continued, though vertebral fracture risk was numerically higher in the holiday group [18]. The decision to continue or pause must be individualized.